Fundraising FoxAltium Capital
Crossover fundNew York · Seed–Growth · 7 people tracked
Find your way into Altium Capital
Each arrow is one introduction. Sign up to fill in the first one.
Ask Cecilia Gonzalo to introduce you to William Clifford
You →Cecilia · together at Oberland Capital →William
Ask Jamie Chen to introduce you to Andrew Loggia
You →Jamie · together at Cowen Group, Inc. →Andrew
Ask Sam Okafor to introduce you to Edward Williams
You →Sam · together at West Hill Corporate Finance →Edward
- Joshua Thomas86 people can intro you
- Deborah Wolfe19 people can intro you
- Jacob Gottlieb5 people can intro you
Sign up to find every way you can get introduced to Altium Capital
- Your email: who you already know at Altium Capital, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Altium Capital team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Altium Capital Management concentrates on long-term healthcare investments, primarily in therapeutics across private ventures and small-cap and micro-cap public companies. The firm provides growth capital to early-stage ventures, often in pre-clinical development phases, and supports companies expected to have transformative catalysts, many raising institutional capital for the first time. Altium favors long-term partnerships with multiple rounds of financing and helps portfolio companies attract additional capital through its investor network. Research and due diligence underpin its conviction-based approach, and the team combines scientific and medical experts with experienced fund managers.
Source: firm website, verified Sep 26, 2026.
Team · 7 people
from the firm's website & curatedWhat they invest in
from 17 of 26 portfolio companiesBiotech ×14Healthtech ×9Medical Devices ×5Deep Tech ×4AI & Machine Learning ×2Digital Health ×2Advanced Manufacturing ×1B2B Marketplaces ×1
HQs:United States×13
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×42 founders×33 founders×1
Investments · 26 tracked
founders shown can be your intro pathBy year:2025 · 12021 · 32019 · 12016 · 16 dated
Delcath Systems is a commercial-stage interventional oncology company developing minimally-invasive treatments for patients with primary and metastatic liver cancers.
BiotechHealthtechMedical DevicesNy, US
Barbra Keck(Executive Officer)inJennifer Simpson(Executive Officer, Director)inGerard Michel(Chief Executive Officer (CEO) and Director)inMarco Taglietti(Director)
BoardRoger Stoll(Director)William Rueckert(Director)
Hyperfine develops diagnostic imaging and data solutions for patient care.
AI & Machine LearningDeep TechHealthtechMedical Devices
Jonathan Rothberg(Founder)Maria Sainz(President, Chief Executive Officer and Director)Brett Hale(Chief Administrative Officer, Chief Financial Officer, Treasurer and Corporate Secretary)Thomas Teisseyre(Chief Operating Officer)
Co-investorsColle Capital PartnersDolby Family Ventures
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Co-investorsHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)BAM ElevateBiotechnology Value FundBlue Owl Capital+1 more
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak HealthDelos Capital+8 more
Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis.
BiotechHealthtechTel Aviv
Adi Mor(Executive Officer, Director)inAdi Mor George(Executive Officer, Director)Jill Quigley(Director)inSigal Fattal(Executive Officer)inMatthew Frankel(Executive Officer)inArnon Aharon(Executive Officer)in
Co-investorsOrbiMedSBI JI Innovation Advisory Ltd.
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
Co-investorsAlta PartnersEisai Innovation, Inc.Fresenius Medical Care VenturesKhosla VenturesLux Capital
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsHBM PartnersKhosla Ventures+13 more
Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)in
BoardJean George(Director)Jason Rhodes(Director)inCarl Gordon(Director)in
Co-investorsLightstone VenturesAtlas VentureOrbiMed
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAmgen VenturesDroia VenturesFrazier Healthcare PartnersNovo Holdings+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+6 more
Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
BiotechHealthtechMedical DevicesNew York, US
Christopher Van Tuyl(Executive Officer)Michael Geffner(Executive Officer)inPete Salzmann(Executive Officer, Director)inJay Stout(Executive Officer)inMelanie Gloria(Executive Officer)inEva Renee Barnett(Executive Officer)
Opus Genetics (formerly Ocuphire) is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies and other treatments for inherited retinal diseases (IRDs) and other retinal and refractive disorders.
BiotechDeep TechDigital HealthWest Bloomfield, US
Mina Sooch(Executive Officer, Director)Meyer Alan(Director)
Co-investorsCapital Midwest FundID Ventures
Palisade Bio develops a PDE4 prodrug platform for treating immune, inflammatory, and fibrotic diseases, with improved pharmacokinetics and tolerability compared to traditional PDE4 inhibitors.
BiotechMedical DevicesCarlsbad, US
I. Richard Garr(Executive Officer, Director)Karl Johe(Executive Officer, Director)Robert McRae(Executive Officer)inHerbert Slade(Executive Officer)J.D. Finley(Executive Officer, Director)JD Finley(Chief Executive Officer)
Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome.
BiotechHealthtechAshburn, US
Michael Myers(Executive Officer, Director)Denise Carter(Executive Officer, Director)inMICHAEL MEYERS(Executive Officer, Director)Sally Bridget Lawlor(Executive Officer)Eyal Leibovitz(Executive Officer)Shai Yarkoni(Executive Officer, Director)
BiotechNew York, US
Raj Mehra(Chief Executive Officer)Michael Golembiewski(Chief Financial Officer)inBRIAN DORSEY(Executive Officer)CATHERINE BOVENIZER(Executive Officer)NEIL MORTON(Executive Officer)
BoardBrian Lian(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CerevelCerevel TherapeuticsQuoinSonnet BiotherapeuticsSonnetbioTimber PharmaceuticalsTimberpharmaVincerxVincerx PharmaYumanityYumanity Therapeutics
Exits · 3
3 IPOsDelcath SystemsNASDAQ: DCTHHyperfineNASDAQ: HYPRSagimet BiosciencesNASDAQ: SGMT
Frequently asked questions
- How many investments has Altium Capital made?
- Altium Capital has 26 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.
- What stage does Altium Capital invest at?
- Altium Capital invests at the Seed, Series A, Growth stages.
- What sectors does Altium Capital focus on?
- Altium Capital focuses on Biotech, Crypto & Web3, Digital Health, Healthtech, Medical Devices.
- Where is Altium Capital located?
- Altium Capital is headquartered in New York, US.
- Who does Altium Capital co-invest with?
- Altium Capital most often shares deals with Frazier Life Sciences, Sanofi Ventures, Khosla Ventures, among 29 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.